This statistic might seem surprising — after all, the therapeutic use of COX inhibitors has ... structures of COX1 and 2, but the presence of the translated intron 1 adds a further 30 amino ...

The COX-2 inhibitors shot to pharmaceutical fame in December 1998 ... Five months later Vioxx (rofecoxib) followed, approved for osteoarthritis, acute pain, and dysmenorrhea.1 But the use for ...

For example, nimesulide is a weak competitive inhibitor of COX-1 but a potent time-dependent inhibitor of COX-2, whereas celecoxib exhibits slow competitive binding and, at higher concentrations ...

"Very lame and imperfect theories are sufficient to suggest useful experiments which serve to correct those theories and give birth to others more perfect. These, then occasion farther experiments ...